Replies to post #202032 on Biotech Values

[DewDiligence]

AEGR +32%/PM on Japan’s approval of Juxtapid for HoPH:

http://finance.yahoo.com/news/aegerion-pharmaceuticals-juxtapid-lomitapide-capsules-200500602.html

Such a sharp rise is odd insofar as AEGR is supposedly being acquired by QLTI (#msg-123312384).

[DewDiligence]

QLTI starts trading under the symbol, NVLN tomorrow:

http://finance.yahoo.com/news/aegerion-pharmaceuticals-inc-qlt-inc-171033476.html

CC today at 4:30pm ET.

[DewDiligence]

NVLN—the renamed AEGR/QLTI—implements 1:5 reverse split and buries the news within a PR on settling a class action lawsuit!

https://globenewswire.com/news-release/2016/12/05/895081/0/en/Aegerion-Pharmaceuticals-a-Subsidiary-of-Novelion-Therapeutics-Enters-into-Agreement-in-Principle-to-Settle-Class-Action-Shareholder-Lawsuit.html

Here are the slides from the 11/30/16 CC on the closing of the QLTI-AEGR merger:
http://ir.novelion.com/common/download/download.cfm?companyid=AMDA-75YS1U&fileid=919411&filekey=D0095795-C2CB-48FA-A75A-CD323C4C338D&filename=NVLN_Closing_Slides_112916_Final.pdf